<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37037165</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Cellular and molecular biomarkers of long COVID: a scoping review.</ArticleTitle><Pagination><StartPage>104552</StartPage><MedlinePgn>104552</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104552</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00117-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long-COVID (LC) encompasses diverse symptoms lasting months after the initial SARS-CoV-2 infection. Symptoms can be debilitating and affect the quality of life of individuals with LC and their families. Although the symptoms of LC are well described, the aetiology of LC remains unclear, and consequently, patients may be underdiagnosed. Identification of LC specific biomarkers is therefore paramount for the diagnosis and clinical management of the syndrome. This scoping review describes the molecular and cellular biomarkers that have been identified to date with potential use for diagnosis or prediction of LC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This review was conducted using the Joanna Briggs Institute (JBI) Methodology for Scoping Reviews. A search was executed in the MEDLINE and EMBASE databases, as well as in the grey literature for original studies, published until October 5th, 2022, reporting biomarkers identified in participants with LC symptoms (from all ages, ethnicities, and sex), with a previous infection of SARS-CoV-2. Non-English studies, cross-sectional studies, studies without a control group, and pre-prints were excluded. Two reviewers independently evaluated the studies, extracted population data and associated biomarkers.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">23 cohort studies were identified, involving 2163 LC patients [median age 51.8 years, predominantly female sex (61.10%), white (75%), and non-vaccinated (99%)]. A total of 239 candidate biomarkers were identified, consisting mainly of immune cells, immunoglobulins, cytokines, and other plasma proteins. 19 of the 239 candidate biomarkers identified were evaluated by the authors, by means of receiver operating characteristic (ROC) curves.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Diverse cellular and molecular biomarkers for LC have been proposed. Validation of candidate biomarkers in independent samples should be prioritized. Modest reported performance (particularly in larger studies) suggests LC may encompass many distinct aetiologies, which should be explored e.g., by stratifying by symptom clusters and/or sex.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Dr. Tebbutt has received funding from the Canadian Institutes of Health Research (177747) to conduct this work. The funding source was not involved in this scoping review, or in the decision to submit this manuscript for publication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esp&#xed;n</LastName><ForeName>Estefan&#xed;a</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chengliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Casey P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assadian</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tebbutt</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Prevention of Organ Failure (PROOF) Centre of Excellence, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; UBC Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: scott.tebbutt@hli.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Long-COVID (LC)</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome (PCS)</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection (PASC)</Keyword></KeywordList><CoiStatement>Declaration of interests All authors have completed the ICMJE uniform disclosure forms. C.Y. reports a grant from the Canadian Institutes of Health Research (grant number: 177747) as payment to their institution to support their work in Canada. The remaining authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37037165</ArticleId><ArticleId IdType="pmc">PMC10082390</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104552</ArticleId><ArticleId IdType="pii">S2352-3964(23)00117-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center for Systems Science and Engineering  . Johns Hopkins Coronavirus Resource Center; 2022. COVID-19 Map - Johns Hopkins Coronavirus Resource Center.https://coronavirus.jhu.edu/map.html</Citation></Reference><Reference><Citation>World Health Organization  WHO coronavirus disease (COVID-19) dashboard with vaccination data | WHO coronavirus (COVID-19) dashboard with vaccination data. World Heal Organ. https://covid19.who.int/ Published online 2022:1-5.</Citation></Reference><Reference><Citation>Richterman A., Meyerowitz E.A., Cevik M. Indirect protection by reducing transmission: ending the pandemic with severe acute respiratory syndrome coronavirus 2 vaccination. Open Forum Infect Dis. 2022;9(2) doi: 10.1093/OFID/OFAB259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/OFID/OFAB259</ArticleId><ArticleId IdType="pmc">PMC8194790</ArticleId><ArticleId IdType="pubmed">35071679</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U., Bedston S., McCowan C., et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305&#x2013;1320. doi: 10.1016/S0140-6736(22)01656-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01656-7</ArticleId><ArticleId IdType="pmc">PMC9560746</ArticleId><ArticleId IdType="pubmed">36244382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J&#xa0;Infect Dis. 2022 doi: 10.1093/INFDIS/JIAC136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAC136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10) doi: 10.1001/JAMANETWORKOPEN.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GB of DLC. Hanson S.W., Abbafati C., et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;1615. doi: 10.1001/JAMA.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. How common is long COVID? Why studies give different answers. Nature. 2022;606(7916):852&#x2013;853. doi: 10.1038/D41586-022-01702-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/D41586-022-01702-2</ArticleId><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;a systematic review and meta-analysis. J&#xa0;Med Virol. 2022;94(1):253. doi: 10.1002/JMV.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JMV.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.D., Ingram J., Sculthorpe N.F. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med. 2021;8:2028. doi: 10.3389/FMED.2021.750378/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2021.750378/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10) doi: 10.1001/JAMANETWORKOPEN.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>A&#xa0;clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/S41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9) doi: 10.1136/BMJGH-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJGH-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N.N., Hoang V.T., Dao T.L., Dudouet P., Eldin C., Gautret P. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review. Eur J Clin Microbiol Infect Dis. 2022;41(4):515. doi: 10.1007/S10096-022-04417-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10096-022-04417-4</ArticleId><ArticleId IdType="pmc">PMC8830952</ArticleId><ArticleId IdType="pubmed">35142947</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q., Li J., Hu X., Bai Y., Zheng Y., Gao Z. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. Front Med. 2021;8:702635. doi: 10.3389/FMED.2021.702635/FULL.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2021.702635/FULL</ArticleId><ArticleId IdType="pmc">PMC8448290</ArticleId><ArticleId IdType="pubmed">34540862</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco A.L., Pacheco R.L., Bagattini &#xc2;.M., Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J Clin Pract. 2021;75(10):14357. doi: 10.1111/IJCP.14357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/IJCP.14357</ArticleId><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramirez D.C., Normand K., Yang Z., Torres-Castro R. Long-term impact of COVID-19: a systematic review of the literature and meta-analysis. Biomedicines. 2021;9(8):900. doi: 10.3390/BIOMEDICINES9080900/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/BIOMEDICINES9080900/S1</ArticleId><ArticleId IdType="pmc">PMC8389585</ArticleId><ArticleId IdType="pubmed">34440104</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11(2):269. doi: 10.3390/PATHOGENS11020269/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PATHOGENS11020269/S1</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G., Monaghan A., Xue F., Mockler D., Romero-Ortu&#xf1;o R. A&#xa0;systematic review of persistent symptoms and residual abnormal functioning following acute covid-19: ongoing symptomatic phase vs. post-covid-19 syndrome. J&#xa0;Clin Med. 2021;10(24):5913. doi: 10.3390/JCM10245913/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM10245913/S1</ArticleId><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657. doi: 10.1016/J.CMI.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55. doi: 10.1016/J.EJIM.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJIM.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F., Veronesi F., Martini L., Landini M.P., Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med. 2021;8:653516. doi: 10.3389/FMED.2021.653516/FULL.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2021.653516/FULL</ArticleId><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G., Diodati F., Puntoni M., et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J&#xa0;Clin Med. 2022;11(6):1541. doi: 10.3390/JCM11061541/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM11061541/S1</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159. doi: 10.1093/FAMPRA/CMAB076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/FAMPRA/CMAB076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-acute sequelae of COVID-19 (PASC) or long COVID: a meta-analysis and systematic review. medRxiv. 2021 doi: 10.1101/2021.11.15.21266377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.15.21266377</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips S., Williams M.A. Confronting our next national health disaster &#x2014; long-haul Covid. N&#xa0;Engl J Med. 2021;385(7):577&#x2013;579. doi: 10.1056/NEJMP2109285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMP2109285</ArticleId><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Naughton A., et al. Longitudinal analysis of COVID-19 patients shows age-associated T cell changes independent of ongoing ill-health. Front Immunol. 2021;12:1593. doi: 10.3389/FIMMU.2021.676932/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.676932/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216. doi: 10.1038/S41590-021-01113-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41590-021-01113-X</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J&#xa0;Investig Med. 2022;70(1):61&#x2013;67. doi: 10.1136/JIM-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JIM-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J&#xa0;Infect Dis. 2021;224(11):1839&#x2013;1848. doi: 10.1093/INFDIS/JIAB490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAB490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M.G., Palladini M., De Lorenzo R., et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138&#x2013;147. doi: 10.1016/J.BBI.2021.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBI.2021.02.021</ArticleId><ArticleId IdType="pmc">PMC7903920</ArticleId><ArticleId IdType="pubmed">33639239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C., Zurbuchen Y., Taeschler P., et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20. doi: 10.1016/J.CELL.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J&#xa0;Thromb Haemost. 2021;19(10):2546. doi: 10.1111/JTH.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JTH.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn Z., Peters M.D.J., Stern C., Tufanaru C., McArthur A., Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):1&#x2013;7. doi: 10.1186/S12874-018-0611-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12874-018-0611-X</ArticleId><ArticleId IdType="pmc">PMC6245623</ArticleId><ArticleId IdType="pubmed">30453902</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters M.D.J., Marnie C., Tricco A.C., et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119&#x2013;2126. doi: 10.11124/JBIES-20-00167.</Citation><ArticleIdList><ArticleId IdType="doi">10.11124/JBIES-20-00167</ArticleId><ArticleId IdType="pubmed">33038124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco A.C., Lillie E., Zarin W., et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467&#x2013;473. doi: 10.7326/M18-0850.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0850</ArticleId><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Schank M., Wang L., et al. Plasma biomarkers for systemic inflammation in COVID-19 survivors. Proteomics Clin Appl. 2022;16(5) doi: 10.1002/PRCA.202200031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PRCA.202200031</ArticleId><ArticleId IdType="pmc">PMC9539278</ArticleId><ArticleId IdType="pubmed">35929818</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., Leavy O.C., Richardson M., et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761&#x2013;775. doi: 10.1016/S2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., et al. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):1&#x2013;18. doi: 10.1186/S12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., Vlok M., Turner S., et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190. doi: 10.1186/S12933-022-01623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12933-022-01623-4</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L.B., Peluso M.J., Ding J., et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight. 2022;7(15) doi: 10.1172/JCI.INSIGHT.160989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI.INSIGHT.160989</ArticleId><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Sans H.M., Forman C.A., et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(5) doi: 10.1212/NXI.0000000000200003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionte C., Sorodoc V., Haliga R.E., et al. Inflammatory and cardiac biomarkers in relation with post-acute COVID-19 and mortality: what we know after successive pandemic waves. Diagnostics. 2022;12(6):1373. doi: 10.3390/DIAGNOSTICS12061373/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/DIAGNOSTICS12061373/S1</ArticleId><ArticleId IdType="pmc">PMC9222082</ArticleId><ArticleId IdType="pubmed">35741183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A., Gennari A., Pommeret F., et al. COVID-19 sequelae and the host proinflammatory response: an analysis from the OnCovid registry. J&#xa0;Natl Cancer Inst. 2022;114(7):979&#x2013;987. doi: 10.1093/JNCI/DJAC057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/JNCI/DJAC057</ArticleId><ArticleId IdType="pmc">PMC9047221</ArticleId><ArticleId IdType="pubmed">35417006</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  . 2021. Post-COVID conditions | CDC. Sav Lives, Prot People.https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>(NICE) NI for H and CE . 2021. Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE; pp. 1&#x2013;111.</Citation></Reference><Reference><Citation>Queiroz M.A.F., Neves P.F.M.D., Lima S.S., et al. Cytokine profiles associated with acute COVID-19 and Long COVID-19 syndrome. Front Cell Infect Microbiol. 2022;12:1. doi: 10.3389/FCIMB.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCIMB.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J.K., Sarkar S., Fram T.R., et al. Duration of post&#x2013;COVID-19 symptoms is associated with sustained SARS-CoV-2&#x2013;specific immune responses. JCI Insight. 2021;6(15) doi: 10.1172/JCI.INSIGHT.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI.INSIGHT.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deeks S.G., Mustapic M., et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol. 2022;91(6):772&#x2013;781. doi: 10.1002/ANA.26350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Tang L., Ma Y., et al. Immunological profiling of COVID-19 patients with pulmonary sequelae. mBio. 2021;12(5) doi: 10.1128/MBIO.01599-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MBIO.01599-21</ArticleId><ArticleId IdType="pmc">PMC8546863</ArticleId><ArticleId IdType="pubmed">34488453</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., Palese A., Venturini M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10):1507&#x2013;1513. doi: 10.1016/J.CMI.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield K.M., Watson R.O., Schneider J.M., et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18(5) doi: 10.1371/JOURNAL.PPAT.1010359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PPAT.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Fern&#xe1;ndez M., Padilla S., et al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13:4801. doi: 10.3389/FIMMU.2022.920627.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2022.920627</ArticleId><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36(6):109518. doi: 10.1016/J.CELREP.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n M., Vig&#xf3;n L., Fuertes D., et al. Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol. 2022;13:1. doi: 10.3389/FIMMU.2022.848886/FULL.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2022.848886/FULL</ArticleId><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou F.S., Michiels S., Shyr Y., Adjei A.A., Oberg A.L. Biomarker discovery and validation: statistical considerations. J&#xa0;Thorac Oncol. 2021;16(4):537&#x2013;545. doi: 10.1016/J.JTHO.2021.01.1616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JTHO.2021.01.1616</ArticleId><ArticleId IdType="pmc">PMC8012218</ArticleId><ArticleId IdType="pubmed">33545385</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter J.V., Pan J., Rai S.N., Galandiuk S. ROC-ing along: evaluation and interpretation of receiver operating characteristic curves. Surgery. 2016;159(6):1638&#x2013;1645. doi: 10.1016/J.SURG.2015.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.SURG.2015.12.029</ArticleId><ArticleId IdType="pubmed">26962006</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Guevara-Coto J., Yogendra R., et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12:700782. doi: 10.3389/FIMMU.2021.700782/FULL.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.700782/FULL</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., Freitag H., Rudolf G., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) J&#xa0;Transl Med. 2022;20(1):1&#x2013;11. doi: 10.1186/S12967-022-03346-2/TABLES/3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12967-022-03346-2/TABLES/3</ArticleId><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodr&#xed;guez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62. doi: 10.1016/J.CYTOGFR.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CYTOGFR.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadotti A.C., de Castro Deus M., Telles J.P., et al. IFN-&#x3b3; is an independent risk factor associated with mortality in patients with&#xa0;moderate and severe COVID-19 infection. Virus Res. 2020;289:198171. doi: 10.1016/J.VIRUSRES.2020.198171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.VIRUSRES.2020.198171</ArticleId><ArticleId IdType="pmc">PMC7510544</ArticleId><ArticleId IdType="pubmed">32979474</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H., Longhi M.S., Wang P., Vergani D., Ma Y. Human CD4+CD25(high)CD127 (low/neg) regulatory T cells. Methods Mol Biol. 2012;806:287&#x2013;299. doi: 10.1007/978-1-61779-367-7_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-367-7_20</ArticleId><ArticleId IdType="pubmed">22057460</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarpak L., Ruetzler K., Safiejko K., et al. Lactate dehydrogenase level as a COVID-19 severity marker. Am J Emerg Med. 2021;45:638. doi: 10.1016/J.AJEM.2020.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AJEM.2020.11.025</ArticleId><ArticleId IdType="pmc">PMC7666711</ArticleId><ArticleId IdType="pubmed">33246860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Y., Han J., Wu X., et al. A&#xa0;novel biomarker for detection of COVID-19 progression. Crit Care. 2020;24(1):1&#x2013;4. doi: 10.1186/S13054-020-03079-Y/FIGURES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13054-020-03079-Y/FIGURES/1</ArticleId><ArticleId IdType="pmc">PMC7309201</ArticleId><ArticleId IdType="pubmed">32576222</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso G., Sfacteria A., Cerami A., Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist. 2004;10(2):93&#x2013;98. doi: 10.1177/1073858403259187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858403259187</ArticleId><ArticleId IdType="pubmed">15070483</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfano D., Franco P., Stoppelli M.P. Modulation of cellular function by the urokinase receptor signalling: a mechanistic view. Front Cell Dev Biol. 2022;10:705. doi: 10.3389/FCELL.2022.818616/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCELL.2022.818616/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC9045800</ArticleId><ArticleId IdType="pubmed">35493073</ArticleId></ArticleIdList></Reference><Reference><Citation>Clec4d - C-type lectin domain family 4 member D - Mus musculus (Mouse) | UniProtKB | UniProt. https://www.uniprot.org/uniprotkb/Q9Z2H6/entry</Citation></Reference><Reference><Citation>Jumeau C., Awad F., Assrawi E., et al. Expression of SAA1, SAA2 and SAA4 genes in human primary monocytes and monocyte-derived macrophages. PLoS One. 2019;14(5) doi: 10.1371/JOURNAL.PONE.0217005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0217005</ArticleId><ArticleId IdType="pmc">PMC6524798</ArticleId><ArticleId IdType="pubmed">31100086</ArticleId></ArticleIdList></Reference><Reference><Citation>FST - Follistatin - Homo sapiens (human) | UniProtKB | UniProt. https://www.uniprot.org/uniprotkb/P19883/entry</Citation></Reference><Reference><Citation>SCGB3A2 secretoglobin family 3A member 2 [Homo sapiens (human)] - Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene/117156</Citation></Reference><Reference><Citation>AGRN - Agrin - Homo sapiens (human) | UniProtKB | UniProt. https://www.uniprot.org/uniprotkb/O00468/entry</Citation></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Sivan M., Delaney B., Evans R., Milne R. Long covid&#x2014;an update for primary care. BMJ. 2022;378 doi: 10.1136/BMJ-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.H., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636&#x2013;1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.A., Knauer M.J., Nicholson M., et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122. doi: 10.1186/S10020-022-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S10020-022-00548-8</ArticleId><ArticleId IdType="pmc">PMC9549814</ArticleId><ArticleId IdType="pubmed">36217108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.W., Su Y., Baloni P., et al. Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nat Biotechnol. 2022;40(1):110&#x2013;120. doi: 10.1038/S41587-021-01020-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41587-021-01020-4</ArticleId><ArticleId IdType="pmc">PMC9206886</ArticleId><ArticleId IdType="pubmed">34489601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuyama Y., Yamakawa K., Kayano K., et al. Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1-year recovery process. Acute Med Surg. 2022;9(1) doi: 10.1002/AMS2.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/AMS2.803</ArticleId><ArticleId IdType="pmc">PMC9597380</ArticleId><ArticleId IdType="pubmed">36311179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi A., Tahmasebi S., Mahmood A., et al. Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J&#xa0;Cell Physiol. 2021;236(4):2829&#x2013;2839. doi: 10.1002/JCP.30047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JCP.30047</ArticleId><ArticleId IdType="pubmed">32926425</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Chen D., Yuan D., et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell. 2020;183(6):1479&#x2013;1495.e20. doi: 10.1016/J.CELL.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;mer B., Knoll R., Bonaguro L., et al. Early IFN-&#x3b1; signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54(11):2650&#x2013;2669.e14. doi: 10.1016/J.IMMUNI.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMMUNI.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemesh A., Su Y., Calabrese D.R., et al. Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting Fc&#x3b5;RI&#x3b3; expression. J&#xa0;Exp Med. 2022;219(11) doi: 10.1084/JEM.20220551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20220551</ArticleId><ArticleId IdType="pmc">PMC9448639</ArticleId><ArticleId IdType="pubmed">36066491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M., Chroscicki P., Swatler J., et al. Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front Immunol. 2022;13:2362. doi: 10.3389/FIMMU.2022.886431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2022.886431</ArticleId><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zaslavsky M., Su Y., et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science. 2022;376(6590) doi: 10.1126/SCIENCE.ABI9591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABI9591</ArticleId><ArticleId IdType="pmc">PMC8995031</ArticleId><ArticleId IdType="pubmed">35258337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N., Dantzer R., Khandaker G.M. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/J.PSYNEUEN.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PSYNEUEN.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., McCann K., O'Brien C., et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. 2022;9(4) doi: 10.1093/OFID/OFAC060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/OFID/OFAC060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zang C., Xu Z., et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2022;29(1):226&#x2013;235. doi: 10.1038/s41591-022-02116-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9(10):815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiken S., Sittenfeld L., Dridi H., Liu Y., Liu X., Marks A.R. Alzheimer&#x2019;s-like signaling in brains of COVID-19 patients. Alzheimers Dement. 2022;18(5):955&#x2013;965. doi: 10.1002/ALZ.12558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ALZ.12558</ArticleId><ArticleId IdType="pmc">PMC9011576</ArticleId><ArticleId IdType="pubmed">35112786</ArticleId></ArticleIdList></Reference><Reference><Citation>Meringer H., Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19(6):345&#x2013;346. doi: 10.1038/s41575-022-00611-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00611-z</ArticleId><ArticleId IdType="pmc">PMC8981882</ArticleId><ArticleId IdType="pubmed">35383321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>